Zydus Cadila has received the final approval from the USFDA to market Acyclovir Ointment USP (US RLD - Zovirax®), 5%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non-life threatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system.
The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.338.1 as compared to the previous close of Rs. 342.25. The total number of shares traded during the day was 56101 in over 771 trades.
The stock hit an intraday high of Rs. 345.05 and intraday low of 338.05. The net turnover during the day was Rs. 19075707.